Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Ettle

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Vaccines|December 23, 2022
Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with OfatumumabTjalf Ziemssen, Marie Groth, Benjamin Ettle, et al.
Human Vaccines & Immunotherapeutics|February 12, 2024
Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumabTjalf Ziemssen, Marie Groth, Benjamin Ettle, et al.
Molecular Neurobiology|May 14, 2015
Oligodendroglia and Myelin in Neurodegenerative Diseases: More Than Just Bystanders?Benjamin Ettle, Johannes C M Schlachetzki, Jürgen Winkler
Vaccines|May 27, 2023
Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple SclerosisTjalf Ziemssen, Eugen Schlegel, Marie Groth, et al.
Pharmacoeconomics|May 15, 2020
Correction to: Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple SclerosisNils-Henning Ness, Dirk Schriefer, Rocco Haase, et al.
Pharmacoeconomics|May 5, 2020
Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple SclerosisNils-Henning Ness, Dirk Schriefer, Rocco Haase, et al.
Journal of Neuroinflammation|August 28, 2016
α-Synuclein deficiency promotes neuroinflammation by increasing Th1 cell-mediated immune responsesBenjamin Ettle, Kristina Kuhbandner, Stefanie Jörg, et al.
Journal of Neurology|January 18, 2020
Correction to: Differentiating societal costs of disability worsening in multiple sclerosisNils-Henning Ness, Dirk Schriefer, Rocco Haase, et al.
Journal of Neurology|December 19, 2019
Differentiating societal costs of disability worsening in multiple sclerosisNils-Henning Ness, Dirk Schriefer, Rocco Haase, et al.
Journal of Medical Internet Research|March 18, 2020
The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation StudyNils-Henning Ness, Rocco Haase, Raimar Kern, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Vaccines|December 23, 2022
Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with OfatumumabTjalf Ziemssen, Marie Groth, Benjamin Ettle, et al.
Human Vaccines & Immunotherapeutics|February 12, 2024
Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumabTjalf Ziemssen, Marie Groth, Benjamin Ettle, et al.
Molecular Neurobiology|May 14, 2015
Oligodendroglia and Myelin in Neurodegenerative Diseases: More Than Just Bystanders?Benjamin Ettle, Johannes C M Schlachetzki, Jürgen Winkler
Vaccines|May 27, 2023
Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple SclerosisTjalf Ziemssen, Eugen Schlegel, Marie Groth, et al.
Pharmacoeconomics|May 15, 2020
Correction to: Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple SclerosisNils-Henning Ness, Dirk Schriefer, Rocco Haase, et al.
Pharmacoeconomics|May 5, 2020
Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple SclerosisNils-Henning Ness, Dirk Schriefer, Rocco Haase, et al.
Journal of Neuroinflammation|August 28, 2016
α-Synuclein deficiency promotes neuroinflammation by increasing Th1 cell-mediated immune responsesBenjamin Ettle, Kristina Kuhbandner, Stefanie Jörg, et al.
Journal of Neurology|January 18, 2020
Correction to: Differentiating societal costs of disability worsening in multiple sclerosisNils-Henning Ness, Dirk Schriefer, Rocco Haase, et al.
Journal of Neurology|December 19, 2019
Differentiating societal costs of disability worsening in multiple sclerosisNils-Henning Ness, Dirk Schriefer, Rocco Haase, et al.
Journal of Medical Internet Research|March 18, 2020
The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation StudyNils-Henning Ness, Rocco Haase, Raimar Kern, et al.
Pageof 3